The estimated Net Worth of Pamela P Palmer is at least $1.13 Million dollars as of 24 August 2023. Pamela Palmer owns over 16,956 units of Acelrx Pharmaceuticals Inc stock worth over $26,448 and over the last 14 years he sold ACRX stock worth over $19,160. In addition, he makes $1,083,330 as Co-Founder, Director, and Chief Medical Officer at Acelrx Pharmaceuticals Inc.
Pamela has made over 8 trades of the Acelrx Pharmaceuticals Inc stock since 2011, according to the Form 4 filled with the SEC. Most recently he sold 16,956 units of ACRX stock worth $19,160 on 24 August 2023.
The largest trade he's ever made was buying 37,000 units of Acelrx Pharmaceuticals Inc stock on 6 August 2018 worth over $101,750. On average, Pamela trades about 4,632 units every 144 days since 2011. As of 24 August 2023 he still owns at least 30,753 units of Acelrx Pharmaceuticals Inc stock.
You can see the complete history of Pamela Palmer stock trades at the bottom of the page.
Dr. Pamela P. Palmer M.D., Ph.D. serves as Co-Founder, Director, Chief Medical Officer of the Company. Dr. Palmer has been on faculty at the University of California, San Francisco since 1996 and is currently a Clinical Professor of Anesthesia and Perioperative Care. Dr. Palmer was Director of UCSF PainCARE-Center for Advanced Research and Education from 2005 to 2009, and was Medical Director of the UCSF Pain Management Center from 1999 to 2005. Dr. Palmer has been a consultant of Omeros Corporation, a biopharmaceutical company, since she co-founded that company in 1994. Dr. Palmer holds an M.D. from Stanford University and a Ph.D. from the Stanford Department of Neuroscience. Dr. Palmer’s extensive clinical and scientific experience in the treatment of acute and chronic pain as well as historical knowledge of our company provides her with the qualifications and skills to serve as a director.
As the Co-Founder, Director, and Chief Medical Officer of Acelrx Pharmaceuticals Inc, the total compensation of Pamela Palmer at Acelrx Pharmaceuticals Inc is $1,083,330. There are 1 executives at Acelrx Pharmaceuticals Inc getting paid more, with Vincent Angotti having the highest compensation of $2,125,050.
Pamela Palmer is 57, he's been the Co-Founder, Director, and Chief Medical Officer of Acelrx Pharmaceuticals Inc since 2005. There are 8 older and 5 younger executives at Acelrx Pharmaceuticals Inc. The oldest executive at Acelrx Pharmaceuticals Inc is Lawrence G. Hamel, 69, who is the Consultant.
Pamela's mailing address filed with the SEC is C/O ACELRX PHARMACEUTICALS, INC., 1850 GATEWAY DRIVE, SUITE 175, SAN MATEO, CA, 94404.
Over the last 14 years, insiders at Acelrx Pharmaceuticals Inc have traded over $25,363,406 worth of Acelrx Pharmaceuticals Inc stock and bought 5,245,025 units worth $26,783,172 . The most active insiders traders include Advisors Llcperceptive Life..., Advisors Llcedelman Josephp..., and Mark Ajaeger Wilfred Ethree.... On average, Acelrx Pharmaceuticals Inc executives and independent directors trade stock every 63 days with the average trade being worth of $109,939. The most recent stock trade was executed by Vincent J. Angotti on 13 December 2023, trading 10,000 units of ACRX stock currently worth $7,300.
acelrx pharmaceuticals inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. the company’s product candidates, dsuvia™ (known as arx-04 outside of the united states) and zalviso®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. dsuvia is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. the phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. in clinical studies, dsuvia demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and v
Acelrx Pharmaceuticals Inc executives and other stock owners filed with the SEC include: